Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Oncology Tests Processed by Year
Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests)
Natera Total Oncology Tests Processed: 800,800.00 tests in FY2025, up 51.6% from a year earlier.
Where the FY2025 figure comes from
“Processed approximately 800,800 oncology tests in the full year 2025, compared to approximately 528,200 in the full year 2024”
Source: Form 8-K Ex 99.1 (2026-02-26) ↗
Total oncology units processed across clinical Signatera MRD, Altera comprehensive genomic profiling, and biopharma clinical trial testing.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 800,800.00 | +51.6% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 528,200.00 | +54.9% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 341,000.00 | +73.6% | Form 8-K Ex 99.1 (2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 196,400.00 | – | Form 8-K Ex 99.1 (2024-02-28) ↗ |
Breakdown
What makes up total Oncology Tests Processed
Cite this data
StockData. (2026). Natera Total Oncology Tests Processed, annual FY2022–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-oncology-tests-processed
See every metric in the Natera KPI table. Data updated Nov 2, 2026.